NCI-2022-04663

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

This Phase 1/2 study is looking at a drug called BLU-222 to see if it is safe and effective for treating advanced solid tumors. Researchers will test BLU-222 both on its own and in combination with other therapies. The main goals of the study are to understand how BLU-222 behaves in the body (pharmacokinetics), assess its safety, and determine if it can shrink tumors and improve patient outcomes

Phase 1/2: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05252416

Clinical Trial Site: Columbia

To see all available clinical trials click here.